Park Perspective: Verso Biosense

Milton Park’s Park Perspective events are designed to lift the lid on world-changing innovations being delivered by occupiers across the Park.

The next event will mark International Women’s Day 2026, where Verso Biosense will share an insight into their early-stage med tech that focuses on monitoring the uterine environment in the female body.

On Thursday 5 March, from 8.30 – 9.30am, join CEO Kate Rowley for a candid discussion that shares key insights into Verso Biosense, where they began, what they are doing today and their vision for the future.

About Verso Biosense

Verso Biosense is an early-stage med tech company answering a question that has existed for a long time – what is going on inside the uterus?

Current techniques only give us a snapshot in time. Yet the uterus is a very dynamic place. So it’s time to change. It’s time to deliver a technology that continuously monitors biomarkers in the uterus. This will help understand more about uterine conditions and the broader implications in women’s health.

Verso Biosense designs and manufacture a series of smart intra-uterine devices fitted with sensors designed to monitor biomarkers in the uterus. These sensors are accompanied by smart accessories that power the device and transmit the personalised data to a secure cloud providing valuable personalised insights into uterine health.

The company currently has two clinical trials for subjects between the ages of 18 – 45, including a trial for those engaged with assistive reproductive technologies.  

Speaker: Kate Rowley CEO

Kate has an exceptionally broad experience garnered from a variety of roles spanning researcher to board member over her 30-year history in the healthcare sector.  

Following success as a post-doctoral researcher in viral technologies, she started her journey in commercialisation of science at the Scottish Association for Marine Science, leading on IP, licensing, commercial services and managing the business Incubator co-located with the research institute. She has spent much of her life sciences career in commercial executive roles leading business development and M&A activities in the health tech arena.

Kate has been an engaged investor and non-exec board member, chairing sub committees and leading VC investment rounds from university spinouts though to growth stage companies. As well as a first-class honours degree in Biotechnology, Kate holds a PhD from the University of Reading and an MBA from the University of Glasgow.

If you work on Milton Park and would like to be our next Park Perspective speaker, please email: ev****@********rk.com.